SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*
Bradsher Neal C

(Last) (First) (Middle)
C/O BROADWOOD CAPITAL, INC.
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [LCTX]

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
☑ Director ☑ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
☑ Form filed by One Reporting Person
☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
OPTION TO PURCHASE COMMON SHARES	$1.3	07/01/2026		A		125,000		(1)	07/01/2036	COMMON SHARES	125,000	$0(2)	125,000	D	
OPTION TO PURCHASE COMMON SHARES	$0.8977							(3)	07/01/2035	COMMON SHARES	75,000		75,000	D	
OPTION TO PURCHASE COMMON SHARES	$0.9541							(3)	07/01/2034	COMMON SHARES	75,000		75,000	D	
OPTION TO PURCHASE COMMON SHARES	$1.41							(3)	07/01/2033	COMMON SHARES	50,000		50,000	D	
OPTION TO PURCHASE COMMON SHARES	$1.57							(3)	07/01/2032	COMMON SHARES	50,000		50,000	D	
OPTION TO PURCHASE COMMON SHARES	$2.86							(3)	07/01/2031	COMMON SHARES	50,000		50,000	D	
OPTION TO PURCHASE COMMON SHARES	$0.8263							(3)	07/01/2030	COMMON SHARES	40,000		40,000	D	
OPTION TO PURCHASE COMMON SHARES	$1.03							(3)	06/30/2029	COMMON SHARES	40,000		40,000	D	

Explanation of Responses:

1. These options will vest and become exercisable on the earlier of: (a) July 1, 2027 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
2. These options were granted to the Reporting Person by the Issuer on July 1, 2026 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
3. These options are currently exercisable.

Neal C. Bradsher, /s/ Neal C. Bradsher 07/02/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.